- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06324786
Brain Mechanisms of Reducing Polysubstance Use
May 1, 2026 updated by: Arizona State University
Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention 2
The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The proposed study will test whether real-time NF could optimize IBMT practice and improve effects in reducing polysubstance use through targeting self-control networks in the brain.
Study Type
Interventional
Enrollment (Estimated)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: YiYuan Tang
- Phone Number: 4807903577
- Email: yiyuan@asu.edu
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Recruiting
- YiYuan Tang
-
Contact:
- YiYuan Tang
- Phone Number: 4807903577
- Email: yiyuan@asu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- At least 18 years old
- Free of any psychiatric diagnoses or medication (besides a substance use disorder (SUD) to alcohol, tobacco, or cannabis)
- In the past month, at least 4 episodes of heavy episodic drinking; at least 3 occasions of cannabis use; and daily cigarette use for at least the past month
- Normal or corrected-to-normal vision
- Written informed consent
- No previous meditation or NF experiences
Exclusion Criteria:
- Any psychiatric diagnoses other than an SUD
- Medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females)
- Excluding cannabis, evidence of recent (past month) illicit drug use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: IBMT
An evidence-based preventive intervention - integrative body-mind training (IBMT) has shown positive effects in reducing stress and improving self-control and brain plasticity.
It has bodifulness and mindfulness components.
|
IBMT is an effortless mindfulness technique
|
|
Experimental: NF
An evidence-based intervention - NF can not only provide real-time feedback for practice but also target the self-control networks, suggesting the possibility of augmenting IBMT effects via NF.
|
NF is a mental training technique.
|
|
Experimental: IBMT + NF
The combined IBMT and NF also show positive effects in reducing substance use.
|
IBMT is an effortless mindfulness technique
NF is a mental training technique.
|
|
Sham Comparator: Sham NF
Sham NF has the same settings as the active NF but does not have correct parameters of stimulation.
|
NF is a mental training technique.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention effects on brain function using Functional Magnetic Resonance Imaging (fMRI)
Time Frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Brain connectivity changes such as anterior and posterior cingulate cortex measured by fMRI resting state imaging
|
The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
|
Intervention effects on brain white matter using fMRI
Time Frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Brain white matter changes such as anterior and posterior cingulate cortex measured by fMRI diffusion tensor imaging
|
The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
|
Intervention effects on brain grey matter using fMRI
Time Frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Brain volume changes such as anterior and posterior cingulate cortex measured by fMRI structural imaging
|
The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention effects on addiction behavior using substance use questionnaires in PhenX Toolkit
Time Frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Intervention leads to a significant reduction in craving and substance use measured by substance use questionnaires in PhenX Toolkit
|
The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2027
Study Registration Dates
First Submitted
March 6, 2024
First Submitted That Met QC Criteria
March 15, 2024
First Posted (Actual)
March 22, 2024
Study Record Updates
Last Update Posted (Actual)
May 4, 2026
Last Update Submitted That Met QC Criteria
May 1, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 2024 IBMT NF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Drug Use
-
Texas Tech UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMultiple Drug UseUnited States
-
Desitin Arzneimittel GmbHBioPharma Services, IncCompleted
-
Chestnut Health SystemsNational Institute on Drug Abuse (NIDA)Active, not recruitingPolysubstance Drug Use (Indiscriminate Drug Use)United States
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesInstituto Nacional de Psiquiatría Dr. Ramón de la FuenteCompletedDrug Use | Harmful Use
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of ArkansasActive, not recruitingDrug UseUnited States
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarActive, not recruiting
-
PT. Kimia Farma (Persero) TbkPT Pharma Metric LabsCompleted
-
PT BernofarmPT Pharma Metric LabsCompleted
-
Umeå UniversityRecruiting
Clinical Trials on IBMT
-
Texas Tech UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMultiple Drug UseUnited States
-
Arizona State UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed